JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.04B |
| 2 |
Truist Financial
TFC
|
+$964M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$909M |
| 4 |
Texas Instruments
TXN
|
+$800M |
| 5 |
Johnson & Johnson
JNJ
|
+$783M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$1.43B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$1.21B |
| 3 |
STI
SunTrust Banks, Inc.
STI
|
+$987M |
| 4 |
Microsoft
MSFT
|
+$980M |
| 5 |
CELG
Celgene Corp
CELG
|
+$929M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 28.14% |
| 2 | Technology | 13.12% |
| 3 | Financials | 12.1% |
| 4 | Healthcare | 9.54% |
| 5 | Consumer Discretionary | 8.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
251
Regeneron Pharmaceuticals
REGN
$76.9B
| $458M | 0.09% |
1,219,887
+764,436
| +168% | +$257M |
2013 Q2
26 quarters
|
|
|
DISH
252
DELISTED
DISH Network Corp.
DISH
| $457M | 0.09% |
12,888,500
+1,653,701
| +15% | +$57.3M |
2013 Q2
26 quarters
|
|
253
Illumina
ILMN
$42B
| $456M | 0.09% |
1,412,923
-234,871
| -14% | -$71.2M |
2013 Q2
26 quarters
|
|
|
WBA
254
DELISTED
Walgreens Boots Alliance
WBA
| $453M | 0.08% |
7,689,062
-694,542
| -8% | -$40M |
2013 Q2
26 quarters
|
|
255
iShares MSCI Canada ETF
EWC
$7.1B
| $452M | 0.08% |
15,132,791
+885,996
| +6% | +$25.8M |
2013 Q2
26 quarters
|
|
256
PUT
SPDR Gold Trust
GLD
$142B
| $451M | 0.08% |
3,158,800
+740,600
| +31% | +$103M |
2013 Q2
26 quarters
|
|
257
Fomento Económico Mexicano
FMX
$40.6B
| $451M | 0.08% |
4,767,091
+28,707
| +0.6% | +$2.64M |
2013 Q2
26 quarters
|
|
258
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.11B
| $444M | 0.08% |
8,831,900
-6,414,500
| -42% | -$491M |
2015 Q2
18 quarters
|
|
259
Phillips 66
PSX
$111B
| $444M | 0.08% |
3,982,373
-317,523
| -7% | -$35.7M |
2013 Q2
26 quarters
|
|
260
PUT
iShares Morningstar Value ETF
ILCV
$1.35B
| $437M | 0.08% |
9,938,000
+5,138,000
| +107% | +$292M |
2014 Q3
21 quarters
|
|
261
Valero Energy
VLO
$125B
| $435M | 0.08% |
4,648,266
-11,211
| -0.2% | -$1.06M |
2013 Q2
26 quarters
|
|
262
Vanguard FTSE Developed Markets ETF
VEA
$230B
| $431M | 0.08% |
9,787,787
+2,371,861
| +32% | +$101M |
2013 Q2
26 quarters
|
|
263
iShares MSCI All Country Asia ex Japan ETF
AAXJ
$3.93B
| $431M | 0.08% |
5,866,886
-1,282,251
| -18% | -$89.7M |
2013 Q2
26 quarters
|
|
264
Biogen
BIIB
$33.3B
| $427M | 0.08% |
1,439,824
+510,618
| +55% | +$142M |
2013 Q2
26 quarters
|
|
|
DFS
265
DELISTED
Discover Financial Services
DFS
| $426M | 0.08% |
5,017,335
+344,222
| +7% | +$28.4M |
2013 Q2
26 quarters
|
|
266
Teladoc Health
TDOC
$1.05B
| $423M | 0.08% |
5,050,198
-1,119,009
| -18% | -$85.2M |
2015 Q3
17 quarters
|
|
267
Schwab US TIPS ETF
SCHP
$16B
| $422M | 0.08% |
14,892,336
-3,979,860
| -21% | -$113M |
2017 Q2
10 quarters
|
|
268
Performance Food Group
PFGC
$14.9B
| $421M | 0.08% |
8,185,843
-62,672
| -0.8% | -$2.87M |
2015 Q4
16 quarters
|
|
269
Take-Two Interactive
TTWO
$39.9B
| $418M | 0.08% |
3,410,964
-373,504
| -10% | -$45.5M |
2013 Q2
26 quarters
|
|
270
AT&T
T
$152B
| $414M | 0.08% |
14,033,541
-3,001,275
| -18% | -$86.7M |
2013 Q2
26 quarters
|
|
271
Energy Transfer Partners
ET
$70.3B
| $407M | 0.08% |
31,734,549
+7,050,082
| +29% | +$86.9M |
2013 Q2
26 quarters
|
|
272
Gilead Sciences
GILD
$187B
| $406M | 0.08% |
6,252,410
-714,261
| -10% | -$46.5M |
2013 Q2
26 quarters
|
|
|
273
PUT
Microsoft
MSFT
$3.97T
| $401M | 0.07% |
2,543,600
+748,500
| +42% | +$110M |
2013 Q2
26 quarters
|
|
274
JPMorgan Chase
JPM
$885B
| $398M | 0.07% |
2,858,142
+5,808
| +0.2% | +$745K |
2014 Q3
21 quarters
|
|
|
SIVB
275
DELISTED
SVB Financial Group
SIVB
| $397M | 0.07% |
1,583,225
+96,682
| +7% | +$22M |
2013 Q2
26 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2019 Portfolio in Review
As of Q4 2019, JP Morgan Chase held 6,136 positions worth $536B, up 6.8% from $502B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q4 2019 filing shows 374 new, 2,295 increased, 2,258 reduced and 490 closed positions. Its largest new stake was XP: 4,912,590 shares worth $189M. The largest sale was Pfizer, an estimated $1.43B.
By sector, the portfolio is most concentrated in Miscellaneous at 28% of assets, up from 27% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q4 2019 buy was XP: 4,912,590 shares worth $189M.
- JP Morgan Chase added most to iShares 20+ Year Treasury Bond ETF in Q4 2019, an estimated $1.04B increase.
- JP Morgan Chase's biggest Q4 2019 reduction was Pfizer, cutting an estimated $1.43B.
- JP Morgan Chase fully exited SunTrust Banks, Inc. in Q4 2019, selling an estimated $987M.
- JP Morgan Chase's ten largest holdings make up 17% of its $536B portfolio in Q4 2019.
- JP Morgan Chase opened 374 new positions and closed 490 in Q4 2019.
- JP Morgan Chase's portfolio value rose 6.8% quarter-over-quarter to $536B.
Based on JP Morgan Chase's 13F filing for Q4 2019, filed 11 Feb 2020.